SEAN BUTTERBAUGH: Open Payments
NPI 1598226490 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$977 in 54 payments from 15 companies in 2025. Trend: 2023 $141 · 2024 $548 · 2025 $977
Food & beverage: $977
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $158 |
| Axsome Therapeutics, Inc. | 6 | $148 |
| Otsuka America Pharmaceutical, Inc. | 7 | $119 |
| Collegium Pharmaceutical, Inc. | 5 | $87 |
| ABBVIE INC. | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 2 | $60 |
| Neurocrine BioSciences, Inc. | 3 | $49 |
| Alkermes, Inc. | 2 | $46 |
| Sage Therapeutics, LLC | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
Products named: CAPLYTA, Auvelity, REXULTI, Jornay PM, VRAYLAR, FANAPT, INGREZZA, ARISTADA.
Industry payments across KY — which companies pay providers there.
